Owkin has announced the first patient dosing in its Phase I clinical trial for OKN4395, an innovative triple inhibitor targeting solid tumors. This milestone emphasizes Owkin’s commitment to leveraging AI in advancing drug development.
Company Information
Company
Owkin
Location
Paris, Ile-de-France, France
About
Owkin is a TechBio company that combines the best of human and artificial intelligence to find the right treatment for every patient. They are on a mission to understand complex biology, derive new multimodal biomarkers through AI, identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Owkin ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.